Yaz and Yasmin remain among Bayer’s top selling pharmaceuticals despite the over 13,000 pending Yaz & Yasmin lawsuits.
According to the Bayer HealthCare Press Center:
The Bayer Group remains on a path of growth. “The upward trend in our life science businesses – HealthCare and CropScience – continued in the third quarter of 2012,” Management Board Chairman Dr. Marijn Dekkers said Tuesday following the publication of the interim report. HealthCare, particularly the Pharmaceuticals business, gained further growth momentum.
Sales of the Bayer Group advanced by 11.5 percent in the third quarter. The currency- and portfolio-adjusted (Fx & portfolio adj.) increase was 5.5 percent. Earnings before interest and taxes (EBIT) fell by 23.7 percent to EUR 838 million. Net special items totaled minus EUR 356 million. Included here were EUR 205 million in further accounting measures taken – mainly based on additional claims asserted but not filed in court – for all cases in connection with the oral contraceptive Yasmin™/YAZ™ of which Bayer is currently aware and which the company considers to be worthy of settlement (venous clot injuries). Among the other special charges were EUR 134 million in restructuring expenses.
Bayer’s highest-selling products include:
- Betaferon – Multiple sclerosis
- Yaz / Yasmin / Yasminella – Hormonal Contraceptive
- Kogenate – Hemophilia
- Nexavar – Cancer
- Adalat – Hypertension
- Mirena – Hormonal Contraceptive
- Avalox – Respiratory Tract Infections
- Levitra – Erectile Dysfunction
- Aspirin Cardio
- Glucobay – Diabetes
You have the right to trust your medication is safe. Tragically, this is not always the case.
Anyone who suffered a blood clot, DVT (Deep Vein Thrombosis), stroke or Pulmonary Embolism after taking Yaz or Yasmin is strongly urged to contact a court appointed Yaz MDL (Multidistrict Litigation) attorney. Steve Maher is a court appointed Yaz MDL Attorney. He represent you, not drug manufacturers or insurance companies.